Occident Group

What they fund

Occident provides initial financing from the seed stage onwards, with checks starting from EUR 500,000 [2]. They invest in innovative deep-tech startups from the life sciences, industrial tech, and digital sectors [2]. The firm targets highly motivated founders with ambitious goals and excellent technologies with broad application possibilities [2]. They also provide follow-up financing for convincing results and confidence in the founder team [2].

Investment thesis

Occident Group acts as a science investor, targeting deep-tech startups that successfully transfer promising scientific findings from research into real-life applications [1]. The firm prioritizes spin-offs from scientific research to ensure a foundation of validated intellectual property and technical expertise [1]. They specifically target deep-tech ventures, aiming to bring rigorous scientific research results directly to end-users and industries [1]. Occident invests its own money, motivated by having actual impact and enabling concrete solutions for societal challenges [1]. The firm supports founders with a strong entrepreneurial mindset, focusing on sustainable long-term success potential [1].

Credibility: The firm's homepage explicitly outlines its focus on deep-tech, scientific spin-offs, and its own capital deployment for societal impact [1].

Value add

Occident offers strong financial backing, a long-term outlook, and wide-ranging areas of expertise as a partner for start-ups [2]. They provide versatile support for portfolio companies with a competent team of experts and their own entrepreneurial experience [2]. The firm emphasizes transparent communication and mutual trust as the basis for cooperation [2].

Fit verdict: Ideal for deep-tech founders needing patient capital and strategic support in the DACH region.

Founder diligence script:

• What is your specific plan for scaling the scientific validation into a commercial product?
• How do you envision Occident's expertise in life sciences aiding your regulatory strategy?
• What are your long-term goals for the company, and how does Occident's exit history align with them?

Portfolio focus

The portfolio clusters around life sciences and deep-tech ventures, including companies like Immitra Bio and Tubulis [1]. Immitra Bio is developing treatments for respiratory diseases, highlighting a focus on medical breakthroughs [1]. Tubulis focuses on antibody-drug conjugates (ADCs) for cancer treatment, demonstrating expertise in complex biotech [1]. The firm has successfully facilitated exits, such as the acquisition of Tubulis by Gilead [1].

Notable investments & exits

Tubulis was acquired by Gilead, marking a successful exit for Occident [1]. Tubulis raised over €300 million in a Series C round led by Venrock Healthcare Capital Partners before the acquisition [1]. Immitra Bio recently secured a CHF 2.4 million Pre-Seed funding round, showing active portfolio growth [1].

Strategic implications

Occident's focus on scientific spin-offs creates a high-barrier-to-entry moat, as they source deals with validated IP that generalist VCs cannot easily replicate. Their self-funded model allows for patient capital, aligning perfectly with the long development cycles typical of deep-tech and life sciences. The successful exit of Tubulis to Gilead signals strong industry relationships, which could be leveraged for future portfolio companies seeking strategic buyers.

Where they could go further

Occident could expand its geographic focus beyond the DACH region to access a larger pool of deep-tech talent and capital, particularly in the US and UK. The firm could establish a dedicated pre-seed fund to capture earlier-stage scientific breakthroughs before they become expensive seed-stage deals. Occident could create a structured mentorship program connecting portfolio companies with industry experts from their exit network, such as Gilead, to accelerate commercialization.